drugset / Trial / NCT01906684
Comprehensive Analysis of Relapse in Multiple Sclerosis
Unknown
20 enrolled
Tanner Foundation for Multiple Sclerosis
Auburn University · collabMallinckrodt · collabiReportoire Inc · collab
NaSingle-groupOpen-labelTreatment
Summary
This study will determine changes in: 1) the immune activity, characterized as the "immunorepertoire;" 2) 7 Tesla MRI brain images; 3) clinical outcomes; and 4) patient reported quality of life outcomes in subjects with relapsing-remitting multiple sclerosis who are treated with Acthar Gel.
Timeline
- Start
- 2013-08
- Primary completion
- 2014-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Acthar | Peptide | 80 iu | Subcutaneous |